Long-term effects of tibolone on ocular functions in postmenopausal women

被引:13
作者
Verit F.F. [1 ]
Oguz H. [2 ]
Ozkul Y. [3 ]
Bozkurt O. [2 ]
机构
[1] Department of Obstetrics and Gynecology, Faculty of Medicine, Harran University
[2] Department of Ophthalmology, Faculty of Medicine, Harran University, Sanliurfa
[3] Department of Neurology, Faculty of Medicine, Harran University, Sanliurfa
关键词
Ocular functions; Postmenopause; Tibolone;
D O I
10.1007/s00404-006-0251-y
中图分类号
学科分类号
摘要
Hormone replacement therapy has been widely used for the prevention of postmenopausal osteoporosis and treatment of climacteric symptoms for many years, but its effect on ocular functions remains unclear. The aim of the study was to evaluate the long-term effects of tibolone on ocular functions in postmenopausal women. A total of 77 healthy women with at least 1 year of spontaneous menopause were enrolled in the study. Forty women were treated with tibolone for 6 months and 37 women were left untreated. All these patients underwent ophthalmic examination including visual acuity, intraocular pressure (IOP), tear functions, blue-on-yellow and white-on-white Humphrey visual field (HVF), visual evoked potentials (VEP) and electroretinography (ERG). There were significant differences in mean deviation of blue-on-yellow HVF, and oscillatory potentials (O1, O2, and O4) in the ERGs of the chronic tibolone users and the control (P < 0.0001, P = 0.001, P < 0.0001 and 0.05, respectively). However, no significant differences were observed in visual acuity, IOP, tear functions, white-on-white HVF and VEP. We concluded that, although tibolone had no effects on visual acuity, IOP, tear functions and VEP, it might cause some early adverse effects on the electrophysiologic and structural characteristics of the retina, which are detected by these sensitive assays. Randomized placebo-controlled studies with larger groups are needed in future research. © 2006 Springer-Verlag.
引用
收藏
页码:255 / 261
页数:6
相关论文
共 49 条
[1]  
Affinito P., Di Spiezio Sardo A., Di Carlo C., Sammartino A., Tommaselli G.A., Bifulco G., Loffredo A., Loffredo M., Nappi C., Effects of hormone replacement therapy on ocular function in postmenopause, Menopause, 10, pp. 482-487, (2003)
[2]  
Abramov Y., Borik S., Yahalom C., Fatum M., Avgil G., Brzezinski A., Banin E., Does postmenopausal hormone replacement therapy affect intraocular pressure?, J Glaucoma, 14, pp. 271-275, (2005)
[3]  
Albertazzi P., Di Micco R., Zanardi E., Tibolone: A review, Maturitas, 30, pp. 295-305, (1998)
[4]  
Altintas O., Caglar Y., Yuksel N., Demirci A., Karabas L., The effects of menopause and hormone replacement therapy on quality and quantity of tear, intraocular pressure and ocular blood flow, Ophthalmologica, 218, pp. 120-129, (2004)
[5]  
Bigsby R.M., Cardenas H., Caperell-Grant A., Grubbs C.J., Protective effects of estrogen in a rat model of age-related cataracts, Proc Natl Acad Sci USA, 96, pp. 9328-9332, (1999)
[6]  
Bui B.V., Fortune B., Ganglion cell contributions to the rat full-Weld electroretinogram, J Physiol, 555, pp. 153-173, (2004)
[7]  
Christodoulakos G.E., Lambrinoudaki I.V., Vourtsi A.D., Panoulis K.P., Kelekis D.A., Creatsas G.C., Mammographic changes associated with raloxifene and tibolone therapy in postmenopausal women: A prospective study, Menopause, 9, pp. 110-116, (2002)
[8]  
Davis V.L., Chan C.C., Schoen T.J., Couse J.F., Chader G.J., Korach K.S., An estrogen receptor repressor induces cataract formation in transgenic mice, Proc Natl Acad Sci USA, 99, pp. 9427-9432, (2002)
[9]  
Doren M., Ruebig A., Holzgreve W., Differential effects on the androgen status of postmenopausal women treated with tibolone and continuous combined estradiol and norethindrone acetate replacement therapy, Fertil Steril, 75, pp. 554-558, (2001)
[10]  
Ederveen A.G., Kloosterboer H.J., Tibolone exerts its protective effect on trabecular bone loss through the estrogen receptor, J Bone Miner Res, 16, pp. 1651-1657, (2001)